Answers are grounded in this paper and cite their sources.
Examines pharmacokinetics and pharmacodynamics in a murine model, indicating potential for treating infections.
Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance determinants. Enmetazobactam (formerly AAI101) is a novel ESBL inhibitor developed in combination with cefepime for empirical treatment of serious Gram-negative infections in settings where ESBLs are prevalent. Cefepime-enmetazobactam has been investigated in a phase 3 trial in patients with complicated urinary tract infections or acute pyelonephritis.
No takes yet. Share an insight, caveat, or question.
Bernhard et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: